Ensifentrine: a novel approach to redefining COPD management and implications for additional respiratory diseases.

Abstract

Introduction: Ensifentrine, recently approved by the FDA for chronic obstructive pulmonary disease (COPD) maintenance treatment, is a novel inhaled therapy with a dual mechanism of action targeting phosphodiesterase (PDE)3 and PDE4. While long-acting bronchodilators and inhaled corticosteroids remain initial guideline-based COPD treatments, persistent symptoms and disease exacerbations highlight an existing unmet need. Ensifentrine offers both bronchodilator and anti-inflammatory benefits, offering the potential to address this treatment gap.

Areas covered: This article reviews the mechanism of action of ensifentrine, details supporting preclinical evidence, and summarizes key clinical studies. It further explores ensifentrine's potential impact on the COPD treatment landscape and its potential applicability in other pulmonary diseases.

Expert opinion: Ensifentrine's dual bronchodilator and anti-inflammatory action offer a promising adjunct to standard COPD treatments, particularly for patients with persistent symptoms despite conventional therapy. It improves lung function, meaningfully reduces exacerbation frequency, reduces symptoms, and enhances quality of life. Its inhaled delivery minimizes systemic exposure and side effects commonly observed with oral PDE inhibitors. Furthermore, its anti-inflammatory properties suggest potential applications in other chronic respiratory diseases, such as asthma and non-cystic fibrosis bronchiectasis.